The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

被引：0
|
作者：
Karl-Anton Kreuzer
Richard R. Furman
Stephan Stilgenbauer
Ronald L. Dubowy
Yeonhee Kim
Veerendra Munugalavadla
Esther Lilienweiss
Hans Christian Reinhardt
Paula Cramer
Barbara Eichhorst
Peter Hillmen
Susan M. O’Brien
Andrew R. Pettitt
Michael Hallek
机构：
[1] University of Cologne,Department I of Internal Medicine
[2] Weill Cornell Medical College,Department III of Internal Medicine
[3] Ulm University Medical Center,Center for Molecular Medicine Cologne, and Cologne Excellence Cluster on Cellular Stress Responses in Aging
[4] Gilead Sciences,Associated Diseases (CECAD)
[5] Inc.,undefined
[6] University of Cologne,undefined
[7] St. James’s University Hospital,undefined
[8] University of California-Irvine,undefined
[9] Irvine Chao Family Comprehensive Cancer Center,undefined
[10] University of Liverpool,undefined
来源：
Leukemia | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：296 / 300
页数：4
相关论文
共 50 条
  • [41] QUALITY OF LIFE BENEFITS OF IDELALISIB WITH RITUXIMAB FOR PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA
    Sullivan, W.
    Lee, D.
    Perard, R.
    Ysebaert, L.
    Leblond, V.
    HAEMATOLOGICA, 2015, 100 : 54 - 54
  • [42] Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG)
    Pula, Bartosz
    Budziszewska, Bozena Katarzyna
    Rybka, Justyna
    Gil, Lidia
    Subocz, Edyta
    Dlugosz-Danecka, Monika
    Zawirska, Daria
    Waszczuk-Gajda, Anna
    Iskierka-Jazdzewska, Elzbieta
    Kopacz, Agnieszka
    Szymczyk, Agnieszka
    Czyz, Jaroslaw
    Lech-Maranda, Ewa
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    ANTICANCER RESEARCH, 2018, 38 (05) : 3025 - 3030
  • [44] COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL
    Gouveia, M.
    Silva, M. G.
    Alarcao, J.
    Fiorentino, F.
    Carda, J.
    Costa, R.
    Mariz, J. M.
    Raposo, J.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2015, 18 (07) : A461 - A462
  • [45] Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Blum, Kristie A.
    Jones, Jeffrey Alan
    Flynn, Joseph M.
    Johnson, Amy J.
    Grever, Michael R.
    Byrd, John C.
    Heerema, Nyla A.
    BLOOD, 2010, 116 (21) : 1019 - 1020
  • [46] No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib
    Barrientos, Jacqueline C.
    Hillmen, Peter
    Salles, Gilles
    Sharman, Jeff
    Stilgenbauer, Stephan
    Gurtovaya, Oksana
    Xing, Guan
    Ruzicka, Bianca
    Bhargava, Pankaj
    Ghia, Paolo
    Pagel, John M.
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 837 - 845
  • [47] A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia.
    Xenakis, Alexander
    Smith, Nathaniel
    Beckerman, Rachel
    Chhatwal, Jagpreet
    Gregory, Stephanie A.
    Pinilla-Ibarz, Javier
    Briggs, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kriachok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Wang, Min Hui
    Yu, Ting
    Ghia, Paolo
    BLOOD, 2021, 138
  • [49] y Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Idelalisib
    Kopel, Jonathan
    Swarup, Sriman
    Sultan, Anita
    Tijani, Lukman
    Phyu, Ei Moe
    Win, Myint Aung
    Htut, Thura Win
    Aung, Ye
    Dash, Akshar
    Han, Myat Min
    Myat, Yin Mon
    Quick, Donald P.
    D'Cunha, Nicholas
    Thein, Kyaw Zin
    BLOOD, 2019, 134
  • [50] The prognostic impact of serum antinuclear antibodies on overall survival in patients with chronic lymphocytic leukemia
    Sun, Qian
    Wang, Li
    Zhu, Hua-Yuan
    Wu, Wei
    Liang, Jin-Hua
    Cao, Lei
    Xia, Yi
    Wu, Jia-Zhu
    Wang, Yan
    Wang, Rong
    Fan, Lei
    Xu, Wei
    Li, Jian-Yong
    LEUKEMIA & LYMPHOMA, 2017, 58 : 28 - 30
12345